Browse > Article
http://dx.doi.org/10.4046/trd.2014.77.6.271

Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer  

Choi, Mihong (Department of Internal Medicine, Center for Diagnostic Oncology, National Cancer Center)
Lee, Youngjoo (Department of Internal Medicine, Center for Diagnostic Oncology, National Cancer Center)
Hwang, Sang Hyun (Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center)
Lee, Jin Soo (Department of Internal Medicine, Center for Diagnostic Oncology, National Cancer Center)
Publication Information
Tuberculosis and Respiratory Diseases / v.77, no.6, 2014 , pp. 271-273 More about this Journal
Abstract
Disease flare-up after discontinuing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been considered as a critical issue in lung cancer patients who have experienced radiologic progression after showing initial durable response. This is a case of systemic nocardiosis that occurred after chronic steroid use for radionecrosis from stereotactic radiosurgery. It was initially thought as a disease flare-up after stopping EGFR-TKI.
Keywords
EGFR Tyrosine Kinase Inhibitor 324674; Nocardia Infections; Carcinoma; Non-Small-Cell Lung; Radiosurgery;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298-303.   DOI
2 Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol 2003;41:4497-501.   DOI   ScienceOn
3 Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010;38: 89-97.   DOI   ScienceOn
4 Kano H, Kondziolka D, Zorro O, Lobato-Polo J, Flickinger JC, Lunsford LD. The results of resection after stereotactic radiosurgery for brain metastases. J Neurosurg 2009;111:825-31.   DOI
5 Petrovich Z, Yu C, Giannotta SL, O'Day S, Apuzzo ML. Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J Neurosurg 2002;97(5 Suppl): 499-506.
6 Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-39.   DOI   ScienceOn